MS and Demyelinating Disorders

Krzysztof Selmaj, MD, PhD, provides his clinical expertise on strategies to monitor patients with relapsing-remitting multiple sclerosis (RRMS) taking sphinogine-1-phospate (S1P) receptor modulators.

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, explains the tissue selectivity of sphinogine-1-phospate (S1P) receptor modulators and the clinical considerations that arise when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, discusses the treatment landscape for relapsing-remitting multiple sclerosis (RRMS) and where sphinogine-1-phospate (S1P) receptor modulators fit in.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ataxia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 21, 2023.

Although popular at the turn of the century, the use of platform injectable therapies has subsided significantly with the introduction of oral agents, with became the most frequently initiated therapies by 2020.

John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.

Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 14, 2023.

Over a 12-week period, the safety profile of a subcutaneous formulation of ocrelizumab was consistent with its original intravenous formulation, along with comparable MRI activity in the brain.

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

The social worker in the Pediatric Multiple Sclerosis Clinic at Children's Hospital of Philadelphia talked about depression and suicidality rates in pediatric patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.

Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 5 minutes]

In this episode of MEDcast, Dr Krieger, Dr Brandstadter, and Dr Bove discuss MS care in patients who are considering pregnancy. They highlight treatment options, monitoring recommendations during and after pregnancy, as well as other crucial considerations when caring for patients with childbearing goals.

The postdoctoral researcher in the department of neurology at John Hopkins School of Medicine talked about indole-3-lactate as a signaling molecule in the gut-brain axis and its potential as a treatment for MS. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Findings from data on patients with various autoimmune disorders who used remibrutinib, a BTK inhibitor in development for multiple sclerosis, reported no safety concerns in laboratory analyses.